These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

999 related articles for article (PubMed ID: 25362207)

  • 1. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
    von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
    Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
    Kompa AR; Lu J; Weller TJ; Kelly DJ; Krum H; von Lueder TG; Wang BH
    Int J Cardiol; 2018 May; 258():192-198. PubMed ID: 29544929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
    Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
    Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
    Lee S; Hwang HS; Song N; Kang GH; Choi KH; Ji E; Song JM; Kang DH
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
    Liu Y; Fan Y; Li J; Chen M; Chen A; Yang D; Guan X; Cao Y
    Biomed Pharmacother; 2021 Jan; 133():110824. PubMed ID: 33378988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
    Suematsu Y; Jing W; Nunes A; Kashyap ML; Khazaeli M; Vaziri ND; Moradi H
    J Card Fail; 2018 Apr; 24(4):266-275. PubMed ID: 29325796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
    Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
    Suematsu Y; Miura S; Goto M; Matsuo Y; Arimura T; Kuwano T; Imaizumi S; Iwata A; Yahiro E; Saku K
    Eur J Heart Fail; 2016 Apr; 18(4):386-93. PubMed ID: 26749570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
    Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
    Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
    Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
    Wang Y; Zhou R; Lu C; Chen Q; Xu T; Li D
    J Am Heart Assoc; 2019 Jul; 8(13):e012272. PubMed ID: 31240976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
    Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
    Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
    Docherty KF; Campbell RT; Brooksbank KJM; Dreisbach JG; Forsyth P; Godeseth RL; Hopkins T; Jackson AM; Lee MMY; McConnachie A; Roditi G; Squire IB; Stanley B; Welsh P; Jhund PS; Petrie MC; McMurray JJV
    Circulation; 2021 Jul; 144(3):199-209. PubMed ID: 33983794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
    Zhang Y; Yuan M; Suo Y; Yang Q; Shao S; Li Y; Wang Y; Bao Q; Liu T; Li G
    Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):848-857. PubMed ID: 35596518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
    Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
    J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
    Liu Y; Zhong C; Si J; Chen S; Kang L; Xu B
    J Hypertens; 2022 Sep; 40(9):1822-1830. PubMed ID: 35943105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial.
    Yin H; Ma L; Zhou Y; Tang X; Li R; Zhou Y; Shi J; Zhang J
    Heart Vessels; 2024 Aug; 39(8):673-686. PubMed ID: 38635062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
    Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
    Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.